Hangzhou Lingzhi Technology
Core products that are thin-film transistor (TFT) semiconductor chips (including corresponding functional materials and portable test/drive systems).
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | CNY20.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Hangzhou Lingzhi Technology, operating as Linkzill, was established in January 2019 and is carving out a niche in the life sciences and semiconductor sectors. The company is headquartered in Hangzhou, China, with a strategic R&D and Business Development Center in Cambridge, UK, to foster global collaboration. In 2023, the firm launched a TFT Bio-semiconductor R&D Center in Hangzhou, underscoring its commitment to the industrialization of thin-film transistor (TFT) technology for life science applications.
The leadership team includes Founder & Co-CEO Dr. Linrun Feng, Partner & Co-CEO Dr. Yixing Yang, Co-founder & CTO Dr. Zhe Liu, Partner & CBio Dr. Kang Kang, and Partner & COO Gaoya Yang. This team possesses extensive experience from prominent universities like the University of Cambridge and companies such as BGI and BOE, blending expertise in both biology and semiconductors. Linkzill's journey includes securing a multi-million dollar Series A funding round in February 2025, led by Proxima Ventures, which followed earlier Pre-A and Pre-A+ rounds involving ZhenFund. These financial milestones are set to accelerate product delivery and support global market expansion.
Linkzill's business model centers on the application of TFT semiconductor technology to DNA synthesis. The company has developed the world's first benchtop DNA synthesizer based on a TFT chip, which offers a new technological path and helps mitigate supply chain risks associated with traditional chips. This approach leverages China's robust TFT semiconductor industry to create low-cost, large-area, and mass-producible consumables for life science equipment. Revenue is generated through the commercialization of its user-end devices, TFT-DNA chips, and synthetic DNA products, which are delivered as oligonucleotide microarrays, oligo pools, and genes. The company serves a diverse client base of over 300 entities, including technology companies, universities, and research institutes across more than 20 countries.
The firm's core product is a platform built on TFT semiconductor biochips. This technology enables high-throughput DNA synthesis, precise droplet manipulation, and in-situ signal sensing. A key offering is the Zhirui TruArray™ Std 4K, a high-throughput oligonucleotide microarray. The platform is designed to support a range of applications, from synthetic biology and innovative drug R&D to pathogenic microbial detection and AI-assisted protein design. By providing a more efficient, integrated, and cost-effective solution for the build and test phases of research, Linkzill is positioning itself as a key equipment provider in the age of AI for science.
Keywords: TFT semiconductor, biochip, DNA synthesis, life sciences, oligonucleotide microarray, synthetic biology, drug research, high-throughput screening, AI for Science, genetic engineering